Intra-Cellular Therapies News

Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105

Futu NewsDec 2 21:32

Mizuho Securities Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Announces Target Price $100

Futu NewsNov 30 01:32

RBC Capital Sticks to Their Buy Rating for Intra-Cellular Therapies (ITCI)

TipRanksNov 28 09:49

UBS Maintains Intra-Cellular Therapies(ITCI.US) With Hold Rating, Raises Target Price to $87

Futu NewsNov 20 02:31

Intra-Cellular Therapies Is Maintained at Overweight by JP Morgan

Dow JonesNov 4 22:35

J.P. Morgan Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $89

Futu NewsNov 4 21:31

Intra-Cellular Therapies Receives Buy Rating Amid Promising Sales Projections and Strategic Developments

TipRanksNov 4 20:37

A Quick Look at Today's Ratings for Intra-Cellular Therapies(ITCI.US), With a Forecast Between $90 to $102

Futu NewsNov 1 21:19

A Quick Look at Today's Ratings for Intra-Cellular Therapies(ITCI.US), With a Forecast Between $79 to $135

Futu NewsOct 31 21:16

Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $100 Price Target

BenzingaOct 30 20:18

Intra-Cellular Therapies Analyst Ratings

BenzingaOct 30 20:17

Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105

Futu NewsOct 22 20:34

Analysts Have Conflicting Sentiments on These Healthcare Companies: Medpace Holdings (MEDP), Biohaven Ltd. (BHVN) and Intra-Cellular Therapies (ITCI)

TipRanksOct 22 20:23

Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Amylyx Pharmaceuticals Inc (AMLX) and Intuitive Surgical (ISRG)

TipRanksOct 21 20:48

Intra-Cellular Therapies Analyst Ratings

BenzingaOct 12 00:30

Morgan Stanley Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $95

Futu NewsOct 11 20:31

Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105

Futu NewsSep 24 20:31

Intra-Cellular Therapies Price Target Maintained With a $130.00/Share by Cantor Fitzgerald

Dow JonesSep 17 00:01

Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $130 Price Target

BenzingaSep 16 23:52

Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman

Seeking AlphaSep 16 03:50